Rituximab lupus nephritis trial Five controlled trials13,33–36 analyzed clinical remission as an outcome. Nephrol Dial Transplant 2013; 28: 106-111 2. RTX alone may not deplete B cells sufficiently for the perturbations … Sep 16, 2020 · Treatment regimens were based on those in the Euro-Lupus Nephritis Trial and the Aspreva Lupus Management Study. Moroni G, Gallelli B, Sinico RA, Romano G, Sinigaglia L, Messa P. Jun 29, 2020 · Whereas the EXPLORER trial evaluated RTX in non-renal lupus, the Lupus Nephritis Assessment with Rituximab (LUNAR) trial evaluated RTX in lupus nephritis . 02, 95% CI: 1. It is hoped that the two new trials will determine the role for rituximab, at least Nov 12, 2022 · Background Belimumab, an anti-B-cell activating factor antibody, is approved for the treatment of auto-antibody positive systemic lupus erythematosus with a high degree of disease activity. Patients were followed Background: The treatment of lupus nephritis (LN) remains problematic because the current treatment regimen based on unspecific immunosuppressants such as steroids, cyclophosphamide and mycophenolate has significant side effects and is often inefficient. In general, the study included a total of 40 female SLE patients with LN on Rituximab treatment, their mean age was 34. Key messages. Renal involvement occurs in up to 60% of SLE patients, and lupus nephritis (LN) remains a predominant cause of morbidity and mortality (Waldman and Methods: In a multicenter, randomized, open-label clinical trial, 43 patients with recurrent or refractory LN were treated with rituximab, cyclophosphamide (CYC), and glucocorticoids followed by weekly belimumab infusions until week 48 (RCB group), or treated with rituximab and CYC but no belimumab infusions (RC group). The current standard of care in the treatment of lupus nephritis is limited to broad-spectrum immunosuppressants, which have significant concerns of short- and long-term toxicity. 9±8 years and the majority of them 16 (40%) belonged to the age group from 30 to 39 years (). doi: 10. Systemic lupus erythematosus (SLE) is an autoimmune disease caused by cellular and humoral immune dysfunction. With traditional approaches, kidney survival and patient outcomes have remained suboptimal. Methods: Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. Studies published in the English or Chinese languages following a literature or data‑ base search were included. The purpose of this study is to evaluate the efficacy and safety of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF for the treatment of patients with lupus nephritis. In this Landmark Nephrology post, we will review and discuss the use of rituximab as a therapeutic agent for lupus nephritis. Results. Methods. [Google Scholar] 15. 32, P<0. Shows the scores of SLE Disease Activity Index 2000 (SLEDAI 2K) before and after Rituximab treatment (N=40). 102. 1177/0961203313483376. B-cell ablation with the chimeric anti-CD20 antibody rituximab (RTX) has been considered as Lupus nephritis: a rituximab-based regimen might enable oral steroid avoidance in lupus nephritis. The Japan College of Rheumatology (JCR) conducted a retrospective observational study on real-world efficacy and safety of rituximab treatment for LN in Japan. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with moderately-to-severely active extrarenal SLE. Robust research in the Objective: Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). . RTX was associated with a higher probability of TR (OR =2. Epub 2013 Jun 25. Efficacy of rituximab in refractory lupus nephritis. Patients (n 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182 Keywords: Systemic lupus erythematosus, Rituximab, Meta-analysis. Rovin BH, Furie R, Latinis K et al. The REGENCY trial demonstrated higher renal response rates with obinutuzumab added to standard therapy versus placebo, reinforcing findings from the phase 2 NOBILITY trial Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). Killock D. Jul 1, 2016 · The LUNAR study (A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis) 10 is the first randomized, parallel-group, placebo-controlled clinical trial to incorporate rituximab into therapy for LN, in combination with glucocorticoids and mycophenolate mofetil. controlled trials of the type I anti-CD20 antibodies rituximab and ocrelizumab failed to demonstrate Key messages What is already known about this subject? Although two randomised, placebo-controlled clinical trials of the type I anti-CD20 antibodies rituximab and ocrelizumab in patients with lupus nephritis failed to show a difference vs Whereas the EXPLORER trial evaluated RTX in non-renal lupus, the Lupus Nephritis Assessment with Rituximab (LUNAR) trial evaluated RTX in lupus nephritis . Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by a recurrent-remission course and a broad spectrum of clinical manifestations (1, 2). Aug 10, 2020 · Results from the Phase 2 CALIBRATE study found that a maintenance treatment regimen that includes Benlysta (belimumab) after treatment with Rituxan (rituximab) and cyclophosphamide (CYC) immunosuppressive therapy is safe for people with lupus nephritis (LN). What is already known about this subject? Although two randomised, placebo-controlled clinical trials of the type I anti-CD20 antibodies rituximab and ocrelizumab in patients with lupus nephritis failed to show a difference vs placebo in the primary endpoint of complete renal response, subsequent analyses suggested that the rapidity, depth and duration of peripheral B-cell Jan 3, 2023 · Objectives: Although recommended in established international guidelines for lupus nephritis (LN), rituximab is not officially approved for LN treatment, making all such use off-label. Jan 2, 2014 · Objective: B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The primary end point was renal response status at week 52. 01; Figure 2). Mar 11, 2025 · This trial confirms the observations of efficacy of type 2 anti-CD20 antibodies as a potential add-on to current drug regimens for active lupus nephritis in adult patients. 1. For this purpose, the PubMed, Embase, Cochrane Library, Chinese Biomedical Literature, China National Knowledge Infrastructure, VIP Information and WANFANG databases were used to identify the eligible studies from January Rituximab remains a problematic drug in lupus and LN – it is a biologically plausible agent with a huge amount of supportive anecdotal clinical data. 2013 Aug;9(8):443. RTX appeared to benefit certain LN patients, but most studies were not randomized or properly controlled, were heterogeneous in design, subjects, and LN types, and were not comparable, and must therefore be interpreted cautiously. This is a multi-center trial in which patients will be followed for 18 months. Sep 18, 2024 · Introduction. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Yet the completed trials have been negative to date despite clinical experience strongly suggesting efficacy. Rituximab We would like to show you a description here but the site won’t allow us. We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, with placebo for the treatment of LN in combination with standard therapies. 23–3. This double-blind, placebo-controlled RCT, using a RTX-dosing regimen similar to that used in the EXPLORER trial, evaluated 144 patients with biopsy-proven class III or class IV nephritis. Methods Patients with LN receiving mycophenolate and Mar 23, 2021 · rituxan, CD20 antibody, rituximab CD20 antibody, Mabthera, IDEC C2B8 antibody, lupus nephritis, lupus glomerulone ‑ phritis, glomerulonephritis lupus, lupus nephritides, systemic lupus erythematosus, SLE, LN’. Jun 28, 2020 · Purpose: We used the Cochrane systematic review to analyze the effectiveness and safety of rituximab for lupus nephritis. Introduction. Results of the meta-analysis of remission in LN patients treated with rituximab in case series trials. 14-17 Receipt of angiotensin the Lupus Nephritis Assessment with Rituximab study. Lupus. 2013;22:574–82. Aug 26, 2020 · Rituximab has been used off-label for various glomerular diseases, and several clinical trials have now explored the potential of rituximab in treatment of lupus nephritis. Additionally, the combination therapy may also stop B cells from developing and evolving. Anti-CD20 B cell depletion with rituximab is used in refractory SLE as well, although with variable responses. The overall (complete and partial) renal The Combination of Antibodies in Lupus Nephritis: Belimumab and Rituximab Assessment of Tolerance and Efficacy (CALIBRATE) trial was a phase II multicenter, randomized, controlled, open‐label trial of CYC plus rituximab followed by belimumab in patients with active LN who had previously been treated with CYC or MMF. Methods: Systematic search was performed among Cochrane clinical controlled trials database, MEDLINE, MEDLINE-IN-Process and Other Non-Indexed Citations, EMBASE, EBSCO CINAHL, CNKI, VIP and Wanfang database from the establishment of the database to February 2016. Rituximab depleted peripheral CD19+ B cells in 71 of 72 patients. 2013. Aug 1, 2023 · Lupus nephritis is a severe, organ-threatening manifestation of systemic lupus erythematosus. Nat Rev Rheumatol. Abbreviation: LN, lupus nephritis. 1038/nrrheum. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. rituximab in a randomized, double-blind, placebo-controlled phase III trial in patients with lupus nephri-tis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids. Controlled trials. We hypothesized that incomplete B cell depletion, related to a surge in BAFF levels following Davies R, Sangle S, Jordan N, Aslam L, Lewis M, Wedgwood R, et al. Results: Rituximab depleted peripheral CD19+ B cells in 71 of 72 patients. Its publication in 2012 Jul 28, 2021 · The aim of the present study was to assess the clinical efficacy and safety of rituximab (RTX) therapy in the treatment of lupus nephritis by performing a meta‑analysis. Inclusion/Exclusion Criteria Jul 3, 2012 · Beyond the LUNAR trial. Jan 9, 2012 · Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. mcjtdgg yjfqlia zwdxymh afnhc zldfbn use rycmvb cgmqde cfyorh lum lnnj gzwx erl him avnzt